GLP-1's for type one diabetes?
a recent study found impressive benefit of GLP1 receptor agonists in patients with Type 1 diabetes (T1D), leading to decreases in cardiovascular and kidney outcomes (see dm1 GLP1 dec cardiovasc NatureMed2026 in dropbox, or https://doi.org/10.1038/s41591-026-04274-0 ) Details : -- this study utilized the Optum Labs Data Warehouse, a national dataset including about 300 million patients from >60 health systems -- the study design was a sequential target trial emulation after propensity matched score weighting (a mouthful, described below in the commentary; this technique is a way to effectively s imulate a randomized controlled trial based on existing data from a large database -- for the study, they found 174,678 individuals with T1D with 6,092,537 person-trials (person-trials includes those patients who were found to start using a GLP-1 at every time period over the course of the study ) -- baseline variables, after weighti...